

EDUCATIONAL MATERIALS

Dissemination of educational materials for

Deferasirox Umedica 90 mg, 180 mg, 360 mg film-coated tablets

PL 60528/0013-0015

Distribution Plan for Deferasirox Umedica Educational Materials

COMMUNICATION PLAN	
Medicinal product(s)	Deferasirox Umedica 90 mg film-coated tablets Deferasirox Umedica 180 mg film-coated tablets Deferasirox Umedica 360 mg film-coated tablets
Active substance(s)	Deferasirox
Marketing authorisation holder(s)	Umedica Laboratories UK Ltd Office No. G42, The Panorama Park Street Ashford, England TN24 8DF
Safety concern and purpose of the communication	Important potential risk: <ul style="list-style-type: none">• Compliance of the posology and biological monitoring• Medication errors due to switching between Deferasirox FCT/granules and generic versions of deferasirox DT
Educational Materials	<ul style="list-style-type: none">• Educational materials for physicians (which also includes a prescriber checklist) and• Patient information pack
Approval date of Educational Materials / RMP version number	<ul style="list-style-type: none">• Approval date of RMP: April 2026• RMP Version number: 0.1
Target audience and planned distribution path including recipients of educational materials	<u>Patient Guide, HCP Guide and Physician Checklist</u> The MAH shall make the aRMM available electronically on an electronic medicines compendium (eMC) website, for all the physician and other healthcare professionals who may prescribe Deferasirox. Hard copies of the educational material shall be made available on request.
Member States / Country where the Educational Materials will be distributed	UK-wide
Dissemination mode	Digital: placing on web-site https://www.medicines.org.uk/emc Paper copy: on request.
Dissemination of educational materials	MAH shall distribute the above-mentioned educational materials prior to launch of the product as per the regulatory requirement.